Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2021

View Archived Issues

CT-859 improves survival in a murine NASH model

New animal model reveals effects of TM6SF2 gene variant on VLDL lipidation

Preclinical data presented for recombinant myxoma virus MC509-N1 in cancer

Adenosine A2A receptor antagonists identified at Adorx Therapeutics

New MAP4K1 inhibitors synthesized at Pfizer

Takeda Pharmaceutical presents new ABCC2 inhibitors

Merck, Cancer Research Technology divulge YAP1/TEAD interaction inhibitors

Sinocelltech patents Fc fragment fusion protein glycoconjugates

Study reports tumors change as patients age

Glycotope's tumor-targeting IL-15-based immunocytokine shows efficacy in preclinical models

Repurposing of riluzole for the treatment of Niemann-Pick disease, type C1

Attenuated measles vaccine expressing the S antigen protects mice and hamsters from SARS-CoV-2

SHP-1 abundance determines the responsiveness of an individual NK cell

Compounds targeting NPC1 protein show promising antiviral activity against SARS-CoV-2

Osteoclasts modified with tetracycline show efficacy in models of heterotopic ossification

ALD-2510 selectively depletes tumor-infiltrating Tregs for activity in vivo

Polycystic ovary syndrome murine model reveals CYP17 involvement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...